Back to Search
Start Over
Pharmacological inhibition of PTEN limits myocardial infarct size and improves left ventricular function postinfarction.
- Source :
-
American journal of physiology. Heart and circulatory physiology [Am J Physiol Heart Circ Physiol] 2010 Apr; Vol. 298 (4), pp. H1198-208. Date of Electronic Publication: 2010 Jan 22. - Publication Year :
- 2010
-
Abstract
- Phosphoinositide 3-kinase (PI3K) mediates myocardium protective signaling through phosphorylation of phosphatidylinositol (Ptdins) to produce Ptdins(3,4,5)P(3). Lipid phosphatase and tensin homolog on chromosome 10 (PTEN) antagonizes PI3K activity by dephosphorylating Ptdins(3,4,5)P(3); therefore, the inhibition of PTEN enhances PI3K/Akt signaling and could prevent myocardium from ischemia-reperfusion (I/R) injury. Here we studied 1) whether the pharmacological inhibition of PTEN by bisperoxovanadium molecules [BpV(HOpic)] attenuates simulated I/R (SIR) injury in vitro and 2) whether the administration of BpV(HOpic) either before or after ischemia limits myocardial infarct size (IS) and ameliorates cardiodysfunction caused by infarction. First, adult rat cardiomyocytes were treated with or without BpV(HOpic) and then exposure to SIR. Second, anesthetized rats received BpV(HOpic) either before or after ischemia. IS was assessed at 4 h reperfusion, and left ventricular function was evaluated by echocardiography at 28 days postreperfusion. As a result, BpV(HOpic) decreased cell death, improved 3-[4,5-yl]-2,5-diphenyltetrazolium bromide (MTT) viability, and reduced apoptosis in cells exposed to SIR. These protective effects of BpV(HOpic) are associated with increased phospho-Akt and the repression of caspase-3 activity. Second, the administration of BpV(HOpic) significantly reduced IS and suppressed caspase-3 activity following I/R injury and consequentially improved cardiac function at 28 day postinfarction. These beneficial effects of BpV(HOpic) are attributed to increases in myocardial levels of phosphorylation of Akt/endothelial nitric oxide synthase (eNOS), ERK-1/2, and calcium-dependent nitric oxide synthase activity. In conclusion, the pharmacological inhibition of PTEN protects against I/R injury through the upregulation of the PI3K/Akt/eNOS/ERK prosurvival pathway, suggesting a new therapeutic strategy to combat I/R injury.
- Subjects :
- Animals
Caspase 3 metabolism
Cells, Cultured
Disease Models, Animal
Extracellular Signal-Regulated MAP Kinases metabolism
Male
Myocardial Infarction metabolism
Myocardial Infarction pathology
Myocardial Reperfusion Injury metabolism
Myocardial Reperfusion Injury pathology
Myocardial Reperfusion Injury prevention & control
Myocytes, Cardiac metabolism
Myocytes, Cardiac pathology
Nitric Oxide Synthase Type III metabolism
PTEN Phosphohydrolase metabolism
Proto-Oncogene Proteins c-akt metabolism
Rats
Rats, Sprague-Dawley
Ventricular Dysfunction, Left physiopathology
bcl-2-Associated X Protein metabolism
Enzyme Inhibitors therapeutic use
Myocardial Infarction drug therapy
PTEN Phosphohydrolase antagonists & inhibitors
Vanadium Compounds therapeutic use
Ventricular Dysfunction, Left drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1522-1539
- Volume :
- 298
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- American journal of physiology. Heart and circulatory physiology
- Publication Type :
- Academic Journal
- Accession number :
- 20097771
- Full Text :
- https://doi.org/10.1152/ajpheart.00915.2009